CClinicalTrials.gg
Not yet recruitingNCT07494396Updated Aug 5, 2026

An AI-Based Erythema Measurement System for Psoriasis Lesions

An observational study in Psoriasis, sponsored by Khon Kaen University. Not yet recruiting at 1 site in Thailand. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Khon Kaen University · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
50
Ages
18 Years to 100 Years
Sex
All
01

Study summary

Psoriasis is a common chronic inflammatory skin disease. Disease severity is commonly assessed using the Psoriasis Area and Severity Index (PASI), in which erythema is graded subjectively on a 0-4 scale. This visual assessment is prone to significant inter- and intra-rater variability.

Although objective tools such as colorimeters provide accurate erythema measurement, their high cost limits routine clinical use. Smartphone imaging combined with artificial intelligence (AI) offers a practical alternative for objective assessment. However, variability in lighting conditions can affect image consistency. Incorporating a color calibration card enables accurate color normalization.

This study aims to develop and validate an AI-based system for measuring erythema in psoriatic lesions using smartphone images with a color card, compared against a standard colorimeter to assess validity and reliability.

02

Conditions studied

  • Psoriasis

Browse trials for

03

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

A dermatology clinic in Srinagarind Hospital

Inclusion criteria

  • Adults aged ≥18 years
  • Diagnosed with psoriasis by a dermatologist
  • Presence of at least five clearly photographable lesions
  • Willing and able to take photographs using a smartphone with both a standard color calibration card and a study-specific color card at home weekly, and submit images via Line or email
  • Willing to have clinical photographs taken at baseline and at a follow-up visit
  • Provides written informed consent to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Presence of skin infection or other lesions that may interfere with color assessment (e.g., tattoos)
  • Use of self-tanning products or substances that alter skin color
  • Inability to perform photography or comply with study procedures
04

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
50 participants (estimated)
Target follow-up
12 Weeks
Patient registry
Yes

Interventions

  • Diagnostic testNo additional drugs(control Group)

    This study is distinct from other clinical studies in that it does not involve any therapeutic intervention or modification of standard patient care. Instead, it evaluates a non-invasive, image-based measurement system that combines smartphone photography, a color calibration card, and artificial intelligence to quantify erythema in psoriasis lesions. Unlike conventional approaches that rely on subjective physician scoring or require specialized and costly equipment, this intervention is designed to be low-cost, accessible, and applicable in real-world settings, including patient self-monitoring at home.

05

What researchers measure

Primary outcomes

  1. To evaluate the accuracy of erythema measurements of psoriatic lesions obtained from an AI-based erythema model (smartphone imaging with a color calibration card) compared with a standard color calibration device (gold standard).

    Time frame: From enrollment to 12 weeks

06

Study locations

1 site
  • Khon Kaen University
    Khon Kaen, Changwat Khon Kaen 40002, Thailand
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07494396
Lead sponsor
Khon Kaen University
Responsible party
Suteeraporn Chaowattanapanit (Associate Professor, Khon Kaen University) — Principal investigator
First posted
Mar 27, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Apr 20, 2027 (estimated)
Completion
Apr 20, 2027 (estimated)
Last update
Aug 5, 2026

Study contacts

Suteeraporn Chaowattanapanit
Contact
csuteeraporn@yahoo.com
+66891879719

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion